Merck Gets FDA Nod for New NC Site and 2 Other Dow Movers to Watch

Merck & Co. (NYSE:MRK): Current price $47.59

Merck reports that the FDA has okayed its site at Durham, North Carolina for the manufacture of bulk varicella used in Merck’s chickenpox and shingles vaccines. Beyond that, Merck wants to get the site approved in future for the output of bulk and finished product for other childhood and shingles vaccines. In 2010, the Durham site had obtained approval for the production of finished chickenpox vaccines, and with the most recent nod, Merck will be able to reinforce its vaccine supply and address the increasing demand for its shingles vaccine, Zostavax.


United Technologies Corp. (NYSE:UTX): Current price $103.75

The government of Canada said Thursday that it could turn aside a $4.8-billion deal to purchase maritime helicopters from United Technologies Corp’s Sikorsky division, as the contract has been beset by delays and problems. A spokeswoman for federal Public Works Minister Diane Finley announced in an e-mailed statement that, “The government is considering other options for the maritime helicopter project. We are conducting an analysis of price and availability of other aircrafts manufactured by other vendors.”


The Procter & Gamble Co. (NYSE:PG): Current price $77.50

Procter & Gamble’s Charmin toilet paper is teaming up with the Denver Broncos and Baltimore Ravens to commence the 2013  football season in style. Charmin is launching its Charmin Relief Project, which is designed to bring consumers “better bathroom experiences” when they are away from home by bringing state-of-the-art restrooms to Denver when the Broncos host the Super Bowl XLVII Champions, the Baltimore Ravens.

Charmin Brand Manager at P&G Janette Yauch commented that, “At Charmin we believe every trip to the bathroom should be something to enjoy. The Charmin Tailgating-Potties provide our version of a bathroom experience touchdown — providing soft, perfect relief when fans need it most.”


Don’t Miss: Here’s How Confusion May Threaten the Success of Obamacare.